This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jiph.2014.07.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Smoking cessation and harm reduction: a systematic overview of ongoing, randomized controlled trials.
BMC Psychiatry
December 2024
Department of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, RWTH Aachen University, Pauwelsstraße 30, Aachen, 52074, Germany.
Background: Smoking remains one of the major public health threats, necessitating substantial scientific and societal interest in further developing and implementing systematic, smoking cessation trials. This review examines ongoing randomized controlled trials (RCTs) on smoking cessation and harm reduction, focusing on adherence to German S3 guidelines for tobacco dependence and identifying areas needing further research and neglected aspects in the implementation of treatment guidelines for tobacco dependence.
Methods: A systematic search was conducted on the International Clinical Trials Registry Platform, comprising multiple trial registries worldwide, to identify ongoing RCTs focusing on smoking cessation and harm reduction.
Current developments in PI3K-based anticancer agents: Designing strategies, biological activity, selectivity, structure-activity correlation, and docking insight.
Bioorg Chem
January 2025
Integrated Drug Discovery Centre, Department of Pharmaceutical Chemistry, Acharya & BM Reddy College of Pharmacy, Bengaluru 560107, Karnataka, India.
Article Synopsis
- The phosphatidylinositol-3 kinase (PI3K) pathway is crucial in various cancers, making it an attractive target for cancer therapies due to its role in cell survival and metastasis.
- Mutations or overexpression in PI3K genes (PIK3CA, PIK3CB, PIK3CD, PIK3CG) lead to treatment failures, prompting ongoing clinical trials of PI3K inhibitors to combat drug resistance.
- Many PI3K inhibitors have faced withdrawal due to safety concerns, but research continues on promising compounds with unique scaffolds to improve therapy efficacy and safety.
The pipeline of immunomodulatory therapies in polymyalgia rheumatica and giant cell arteritis: A systematic review of clinical trials.
Autoimmun Rev
September 2024
Service de Rhumatologie, Centre National de Référence des Maladies Auto-immunes et Systémiques Rares (RESO), Hôpitaux Universitaires de Strasbourg, F-67000 Strasbourg, France; Département Universitaire de Pharmacologie, Addictologie, Toxicologie et Thérapeutique (DUPATT), Université de Strasbourg, Strasbourg, France; Center for Clinical Investigation, INSERM U1434, Strasbourg, France. Electronic address:
Introduction: The objective of this systematic review was to provide an overview of current developments and potentially available therapeutic options for polymyalgia rheumatic (PMR) and giant cell arteritis (GCA), in the coming years.
Methods: We conducted a systematic review of 17 national and international clinical trial databases for all disease-modifying anti-rheumatic drugs (DMARDs) for PMR and GCA that are already marketed, in clinical development or withdrawn. The search was performed on January 2024, with the keywords "polymyalgia rheumatica" and "giant cell arteritis".
Quality of life, functioning and participation of children and adolescents with visual impairment: A scoping review.
Res Dev Disabil
August 2024
SC Neurologia, Salute Pubblica, Disabilità, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.
Background: Vision has a key role in children's neuromotor, cognitive and social development. Children with visual impairment attain developmental milestones at later stages and are at higher risk of developing psychological disorders and social withdrawn.
Aims: We performed a scoping review to summarize the mostly used instruments assessing the impact of visual impairment on quality of life, functioning and participation of children and adolescents.
Oncology's trial and error: Analysis of the FDA withdrawn accelerated approvals.
Life Sci
June 2024
Massachusetts College or Pharmacy and Health Sciences, Boston, MA 02115, United States of America. Electronic address:
Launched in 1992, the FDA accelerated approval program grants drugs indicated in rare/life threatening diseases the ability to be marketed at a faster pace than through the traditional track. Each manufacturing company presents its drug to the FDA, and within 60 days it will determine if the drug is eligible for this path. Many drugs that were initially approved through this route, subsequently did not demonstrate their clinical benefits.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!